Dr. Jonathan Aschoff
Dr. Jonathan Aschoff is a managing director at Opus National Capital Markets. Prior to joining the firm in 2016, he held positions as a senior biotechnology analyst at Brean Murray, Carret & Co. and Friedman Billings Ramsey & Co. Inc., as a senior analyst at what is now RBC Inc. and also served as an analyst at Sturza Institutional Research. Prior to his work on Wall Street, Dr. Aschoff was a research technician at New England Medical Center. It was at Tufts University that Dr. Aschoff earned his Ph.D. in molecular biology and microbiolog,y as well as his bachelor's degree in biology.
Recent Articles
Biotech Co.'s Target Price Significantly Higher Than Current 03/19/2024
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.
NY Biotech Has Potentially Game Changing Anxiety Therapy 03/07/2024
Mind Medicine (MindMed) Inc. recently announced positive results from its Phase 2b trial of MM120 in generalized anxiety disorder, according to a Roth MKM research note.
Biotech Co. Reports Encouraging ALS Data but FDA Wants More 12/21/2023
Salt Lake City-based Clene Inc. reported both encouraging clinical data and a regulatory setback for its ALS drug candidate CNM-Au8, reported Roth MKM.
Bioscience Co. Expands Collaboration 12/19/2023
This bioscience company's price target implies 680% upside, according to a Roth MKM report.
Drugs Show Anti-Cancer Effects on Myeloma Cells 12/06/2023
These positive results bode well for the biopharma's two polyamine inhibitors as potential treatments for multiple myeloma, noted a ROTH Capital Markets report.
Arizona Biotech Advances Multiple Cell Therapies 11/16/2023
Roth MKM has a US$30 price target on this biotech company based on progress across its regenerative medicine pipeline, including upcoming Phase 1/2 data.
New CAR-T Therapy Shows Potency in Certain Patients 10/04/2023
Study results for patients with relapsed/refractory multiple myeloma continue to be "favorable," noted a ROTH Capital Partners report.
Approved Drug for Skin Condition Shown Safe at Higher Dose 09/01/2023
Based on these positive Phase 1 trial results in actinic keratosis, the biopharma developer will seek label expansion in the U.S., noted a ROTH Capital Partners report.
Recent Quotes
"The freedom to forego Phase 3 testing for Rexista has saved IPCI at least $20M."
—
Dr. Jonathan Aschoff, Brean Capital
(4/15/16)
more >
